Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TARA

Protara Therapeutics Inc

Jul 26 • 04:00PM ET

2.35

Dollar change +0.06
Percentage change 2.62	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.74	Insider Own	7.36%	Shs Outstand	20.59M	Perf Week	5.38%
Market Cap	48.39M	Forward P/E	-	EPS next Y	-3.65	Insider Trans	-24.15%	Shs Float	19.07M	Perf Month	20.20%
Income	-42.47M	PEG	-	EPS next Q	-0.74	Inst Own	42.27%	Short Float	9.44%	Perf Quarter	-22.95%
Sales	0.00M	P/S	-	EPS this Y	-0.45%	Inst Trans	-2.32%	Short Ratio	6.58	Perf Half Y	0.00%
Book/sh	5.11	P/B	0.46	EPS next Y	-1.84%	ROA	-48.67%	Short Interest	1.80M	Perf Year	-13.28%
Cash/sh	2.68	P/C	0.88	EPS next 5Y	-	ROE	-55.45%	52W Range	1.04 - 5.24	Perf YTD	25.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.98%	ROI	-67.81%	52W High	-55.15%	Beta	1.82
Dividend TTM	-	Quick Ratio	10.53	Sales past 5Y	0.00%	Gross Margin	-	52W Low	125.96%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	10.53	EPS Y/Y TTM	34.41%	Oper. Margin	0.00%	RSI (14)	50.29	Volatility	6.89% 10.34%
Employees	27	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	27.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-21.41%	Payout	-	Rel Volume	0.36	Prev Close	2.29
Sales Surprise	-	EPS Surprise	-5.43%	Sales Q/Q	-	Earnings	May 02 BMO	Avg Volume	273.39K	Price	2.35
SMA20	5.24%	SMA50	-7.75%	SMA200	-7.10%	Trades		Volume	98,679	Change	2.62%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

Jun-24-24 05:06PM	Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.83%
May-21-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-02-24 12:54PM	TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-24 09:55AM	Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:04AM	Loading…
Apr-05-24 08:04AM	Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing (GlobeNewswire) -9.70%
08:02AM	Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC (GlobeNewswire)
Mar-13-24 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -7.45%
Jan-31-24 07:30AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
08:30AM	Loading…
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Oct-24-22 08:35AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-06-22 08:00AM	Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
08:00AM	Loading…
Aug-09-22 08:00AM	Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Jun-21-22 08:00AM	Protara Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire)
May-26-22 05:11PM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +5.44%
May-17-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:32AM	Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 08:00AM	Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations (GlobeNewswire)
May-05-22 08:00AM	Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Apr-11-22 09:55AM	Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? (Zacks) -6.17%
Mar-24-22 08:00AM	Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Mar-23-22 10:00AM	Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? (Zacks) +5.06%
Mar-09-22 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview (GlobeNewswire)
Mar-08-22 05:50AM	Protara Therapeutics, Inc. (NASDAQ:TARA) insider upped their holding by 222% earlier this year (Simply Wall St.)
Mar-02-22 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.67%
Feb-01-22 08:00AM	Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference (GlobeNewswire) +8.25%
Jan-10-22 08:00AM	Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-04-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-08-21 11:15AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-04-21 08:00AM	Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Oct-25-21 04:45PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-21 07:00AM	Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +11.85%
Sep-17-21 04:05PM	Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-13-21 07:00AM	Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
Sep-09-21 10:31AM	A number of insiders bought Protara Therapeutics, Inc. (NASDAQ:TARA) stock last year, which is great news for shareholders (Simply Wall St.)
Sep-07-21 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-05-21 08:00AM	Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview (GlobeNewswire)
Jul-07-21 08:00AM	Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Jun-22-21 07:30AM	ProBility Media Provides Corporate Update (PR Newswire)
Jun-10-21 08:00AM	Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors (GlobeNewswire)
May-13-21 08:00AM	Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
May-06-21 07:30AM	Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview (GlobeNewswire) -5.69%
Apr-23-21 07:00AM	Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) -18.41%
Apr-19-21 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-12-21 11:12AM	The Dip in These 3 Stocks Is a Buying Opportunity, Say Analysts (TipRanks)
Mar-30-21 07:01AM	Do Insiders Own Lots Of Shares In Protara Therapeutics, Inc. (NASDAQ:TARA)? (Simply Wall St.)
Mar-11-21 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview (GlobeNewswire) +6.40%
Mar-10-21 08:00AM	Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire)
Feb-04-21 08:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-02-21 08:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors (GlobeNewswire)
Dec-16-20 11:07PM	Is TARA A Good Stock To Buy Now? (Insider Monkey)
Dec-07-20 04:30PM	Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer (GlobeNewswire)
Dec-03-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-20 07:00AM	Protara Therapeutics to Present at Upcoming Virtual Investor Conferences (GlobeNewswire)
Nov-12-20 07:15AM	Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Nov-11-20 07:00AM	Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference (GlobeNewswire)
Nov-04-20 07:00AM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-28-20 03:12PM	What Type Of Shareholders Make Up Protara Therapeutics, Inc.'s (NASDAQ:TARA) Share Registry? (Simply Wall St.)
Sep-22-20 08:13AM	Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire)
Sep-21-20 04:01PM	Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock (GlobeNewswire) -7.97%
Sep-08-20 07:00AM	Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications (GlobeNewswire) -6.09%
Sep-02-20 05:49PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-03-20 07:00AM	Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview (GlobeNewswire)
Jul-28-20 07:00AM	Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations (GlobeNewswire) +5.29%
Jul-24-20 07:00AM	Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors (GlobeNewswire)
Jul-03-20 06:34PM	Hedge Funds Have Never Been This Bullish On Protara Therapeutics, Inc. (TARA) (Insider Monkey)
Jul-02-20 07:59PM	CORRECTION Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-20 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.74%
May-26-20 08:30AM	Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease (GlobeNewswire) +13.98%
May-13-20 08:00AM	Protara Therapeutics Announces First Quarter 2020 Financial Results and Business Overview (GlobeNewswire) -8.46%
May-11-20 08:38AM	ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics (GlobeNewswire)
May-05-20 04:05PM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-20 07:00AM	ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-11-20 08:00AM	ArTara Therapeutics Appoints Blaine Davis as Chief Financial Officer (GlobeNewswire)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Jul 16 '24	Sale	2.44	11,396	27,828	56,500	Jul 18 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 11 '24	Sale	2.40	47,993	115,346	60,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 10 '24	Sale	2.31	18,061	41,685	75,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 09 '24	Sale	2.21	8,497	18,811	80,000	Jul 11 07:56 PM
Opaleye Management Inc.	10% Owner	Jul 01 '24	Sale	2.12	8,288	17,598	87,500	Jul 03 02:00 PM
Opaleye Management Inc.	10% Owner	Jun 28 '24	Sale	2.07	17,994	37,334	85,000	Jun 28 06:45 PM
Opaleye Management Inc.	10% Owner	Jun 27 '24	Sale	2.26	46,574	105,169	90,000	Jun 28 06:45 PM
Opaleye Management Inc.	10% Owner	Jun 25 '24	Sale	2.26	12,725	28,734	102,471	Jun 27 04:05 PM
Opaleye Management Inc.	10% Owner	May 31 '24	Sale	2.90	5,824	16,895	108,696	May 31 04:05 PM
Opaleye Management Inc.	10% Owner	May 30 '24	Sale	2.94	9,230	27,113	114,520	May 31 04:05 PM
Opaleye Management Inc.	10% Owner	May 22 '24	Sale	3.02	9,800	29,596	123,750	May 23 07:01 PM
Opaleye Management Inc.	10% Owner	May 21 '24	Sale	3.06	33,000	100,838	124,250	May 23 07:01 PM
Opaleye Management Inc.	10% Owner	May 17 '24	Sale	3.25	70,885	230,326	126,050	May 17 07:48 PM
Opaleye Management Inc.	10% Owner	May 10 '24	Sale	3.11	151,700	472,424	2,380,294	May 10 06:57 PM
Opaleye Management Inc.	10% Owner	May 09 '24	Sale	3.09	30,600	94,526	2,531,994	May 10 06:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARA

Protara Therapeutics Inc

Upgrade your FINVIZ experience